Mexico Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in the sector, and exports around USD 6.4 billion worth of medical devices annually, driven by major investments from global names…
Mexico Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent according to a 2023 CANIFARMA and INEGI study. That makes it, on paper, appear a highly attractive sector for investment,…
Mexico In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms of prevalence, a full two-thirds of the adult Mexican population are nowadays classified as overweight or obese. “This is a…
Mexico Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an economic outflow of over 240 million dollars per annum in the process. Indeed, most of the major biopharma multinationals now…
Global A new book by two pharma industry experts offers the first truly global perspective on the complexities of market access. Even the most innovative drug is useless if patients cannot afford or access it. As pharmaceutical innovation advances, market access strategies – determining who gets a drug, at what…
Puerto Rico Puerto Rico leads all US jurisdictions in biopharmaceutical exports, shipping to over 120 countries. With a rapidly expanding life sciences sector and growing pharma logistics capabilities, the island is positioning itself as a global hub—but industry leaders say there’s still work to be done. Life Sciences and Logistics Dynamo…
Saudi Arabia Extending not only lifespan, but “healthspan,” and ensuring people live healthier lives for longer is moving beyond purely clinical settings. Experts gathered last week at the Global Healthspan 2025 Summit in Riyadh, Saudi Arabia focused on factors such as lifestyle, the role of virtual tools, and a more holistic approach…
USA Since Christopher Viehbacher took the reins of Biogen in 2022, he has launched a USD 1 billion cost-cutting and priority refocusing plan, made significant deals, and launched the firm’s Alzheimer’s drug Legembi. But snags slowing the uptake of the Eisai-partnered med and the fall in sales of its multiple sclerosis…
Saudi Arabia Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease. As people live longer, the threat of age-related diseases deepens. Alzheimer’s, one of the cruellest such diseases, therefore represents an increasingly urgent public health challenge in…
Saudi Arabia Amr Kenawi, General Manager at Zimmer Biomet in Saudi Arabia, shares his perspective on the country’s evolving healthcare landscape and the company’s role in supporting Vision 2030. Kenawi discusses Zimmer Biomet’s strategic shift from product distribution to offering integrated musculoskeletal solutions, the introduction of cutting-edge technologies like robotics, and the…
Saudi Arabia Saudi Arabia is rapidly shaping its future as a global research powerhouse, channelling unprecedented resources into translational research, clinical trials, and genomics. At the heart of this transformation is the Saudi NIH, driving 13 key research priorities and forging strategic global partnerships. Speaking at The Global Healthspan Summit (GHS 2025)…
Saudi Arabia Despite groundbreaking advances in longevity science, one fundamental challenge remains: how to turn wellness into a scalable, investable industry. Speaking at The Global Healthspan Summit (GHS 2025) in Riyadh, Dr. Mehmood Khan, CEO of the Hevolution Foundation, argues that without a structured economic model, healthy longevity will remain an untapped…
See our Cookie Privacy Policy Here